Iovance Biotherapeutics/$IOVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Iovance Biotherapeutics
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Ticker
$IOVA
Sector
Primary listing
Employees
838
Headquarters
Website
IOVA Metrics
BasicAdvanced
$923M
-
-$1.23
0.88
-
Price and volume
Market cap
$923M
Beta
0.88
52-week high
$12.50
52-week low
$1.64
Average daily volume
23M
Financial strength
Current ratio
3.271
Quick ratio
2.796
Long term debt to equity
6.456
Total debt to equity
7.612
Profitability
EBITDA (TTM)
-376.294
Gross margin (TTM)
20.60%
Net profit margin (TTM)
-161.44%
Operating margin (TTM)
-170.02%
Effective tax rate (TTM)
-0.05%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-27.42%
Return on equity (TTM)
-53.16%
Valuation
Price to revenue (TTM)
3.341
Price to book
1.25
Price to tangible book (TTM)
2.17
Price to free cash flow (TTM)
-2.494
Free cash flow yield (TTM)
-40.09%
Free cash flow per share (TTM)
-1.022
Growth
Revenue change (TTM)
636.99%
Earnings per share change (TTM)
-26.30%
3-year earnings per share growth (CAGR)
-19.95%
10-year earnings per share growth (CAGR)
8.18%
What the Analysts think about IOVA
Analyst ratings (Buy, Hold, Sell) for Iovance Biotherapeutics stock.
IOVA Financial Performance
Revenues and expenses
IOVA Earnings Performance
Company profitability
IOVA News
AllArticlesVideos
Here's why Iova stock surged 32% today and why the rally might not be over
Invezz·4 weeks ago
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
Business Wire·1 month ago
IOVA Deadline: Rosen Law Firm Urges Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Iovance Biotherapeutics stock?
Iovance Biotherapeutics (IOVA) has a market cap of $923M as of August 18, 2025.
What is the P/E ratio for Iovance Biotherapeutics stock?
The price to earnings (P/E) ratio for Iovance Biotherapeutics (IOVA) stock is 0 as of August 18, 2025.
Does Iovance Biotherapeutics stock pay dividends?
No, Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders as of August 18, 2025.
When is the next Iovance Biotherapeutics dividend payment date?
Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Iovance Biotherapeutics?
Iovance Biotherapeutics (IOVA) has a beta rating of 0.88. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.